Proteins > Ribosyldihydronicotinamide dehydrogenase [quinone]
Page last updated: 2024-08-07 13:02:16
Ribosyldihydronicotinamide dehydrogenase [quinone]
A ribosyldihydronicotinamide dehydrogenase [quinone] that is encoded in the genome of human. [PRO:DNx, UniProtKB:P16083]
Synonyms
EC 1.10.5.1;
NRH dehydrogenase [quinone] 2;
NRH:quinone oxidoreductase 2;
Quinone reductase 2;
QR2
Research
Bioassay Publications (27)
| Timeframe | Studies on this Protein(%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (18.52) | 29.6817 |
| 2010's | 21 (77.78) | 24.3611 |
| 2020's | 1 (3.70) | 2.80 |
Compounds (243)
Drugs with Inhibition Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| melatonin | Homo sapiens (human) | IC50 | 7.3161 | 8 | 8 |
| melatonin | Homo sapiens (human) | Ki | 0.0422 | 2 | 2 |
| n-acetylserotonin | Homo sapiens (human) | IC50 | 9.9000 | 1 | 1 |
| 4,5,6,7-tetrabromo-2-azabenzimidazole | Homo sapiens (human) | IC50 | 12.8000 | 1 | 1 |
| aminoglutethimide | Homo sapiens (human) | IC50 | 0.2700 | 1 | 1 |
| chloroquine | Homo sapiens (human) | IC50 | 1.5000 | 1 | 1 |
| perhexiline | Homo sapiens (human) | IC50 | 148.0000 | 1 | 1 |
| prazosin | Homo sapiens (human) | IC50 | 0.0078 | 1 | 1 |
| primaquine | Homo sapiens (human) | IC50 | 7.5000 | 1 | 1 |
| imatinib | Homo sapiens (human) | IC50 | 0.1750 | 3 | 3 |
| imatinib | Homo sapiens (human) | Ki | 0.0390 | 1 | 1 |
| aminacrine | Homo sapiens (human) | IC50 | 0.4450 | 2 | 2 |
| naphthoresorcinol | Homo sapiens (human) | IC50 | 3.3000 | 1 | 1 |
| 4-methylquinolin-2(1H)-one | Homo sapiens (human) | IC50 | 375.2333 | 2 | 3 |
| 1-methoxyphenazine | Homo sapiens (human) | IC50 | 31.1000 | 1 | 1 |
| 2-iodomelatonin | Homo sapiens (human) | IC50 | 1.1000 | 2 | 2 |
| 2-iodomelatonin | Homo sapiens (human) | Ki | 0.0065 | 1 | 1 |
| furamidine | Homo sapiens (human) | IC50 | 0.0350 | 1 | 1 |
| c 1311 | Homo sapiens (human) | IC50 | 0.1370 | 2 | 2 |
| c 1310 | Homo sapiens (human) | IC50 | 0.0350 | 2 | 2 |
| dabigatran | Homo sapiens (human) | IC50 | 10.5000 | 2 | 2 |
| dabigatran | Homo sapiens (human) | Ki | 60.0000 | 1 | 1 |
| resveratrol | Homo sapiens (human) | IC50 | 1.3972 | 12 | 12 |
| resveratrol | Homo sapiens (human) | Ki | 0.0880 | 1 | 1 |
| s 1033 | Homo sapiens (human) | IC50 | 1.0905 | 2 | 2 |
| 5-methoxycarbonylamino-n-acetyltryptamine | Homo sapiens (human) | IC50 | 0.0394 | 3 | 3 |
| 4,5,6,7-tetrabromobenzimidazole | Homo sapiens (human) | IC50 | 0.0794 | 1 | 1 |
| pterostilbene | Homo sapiens (human) | IC50 | 5.1000 | 1 | 1 |
| casein kinase ii | Homo sapiens (human) | IC50 | 0.4840 | 1 | 1 |
| 4,3',5'-tri-o-methylpiceatannol | Homo sapiens (human) | IC50 | 15.0000 | 1 | 1 |
| 3,3',4,5'-tetramethoxy-trans-stilbene | Homo sapiens (human) | IC50 | 37.1000 | 1 | 1 |
| 3,4',5-trimethoxystilbene | Homo sapiens (human) | IC50 | 14.6000 | 1 | 1 |
| penicillin v | Homo sapiens (human) | IC50 | 2.7000 | 1 | 1 |
| 3,4,4'-trihydroxy-trans-stilbene | Homo sapiens (human) | IC50 | 6.0000 | 1 | 1 |
| 4-n-butyl-1-(4-(2-methylphenyl)-4-oxo-1-butyl)-piperidine hydrogen chloride | Homo sapiens (human) | Ki | 1.0000 | 1 | 1 |
| ammosamide b | Homo sapiens (human) | IC50 | 0.0610 | 1 | 1 |
| pf-04418948 | Homo sapiens (human) | IC50 | 0.5300 | 1 | 0 |
| pf-04418948 | Homo sapiens (human) | Ki | 0.5200 | 1 | 0 |
Drugs with Activation Measurements
| Drug | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Publication(s) |
|---|
| 4,5,6,7-tetrabromo-2-azabenzimidazole | Homo sapiens (human) | Kd | 7.1100 | 1 | 1 |
| fasudil | Homo sapiens (human) | Kd | 2.4510 | 1 | 1 |
| 4-(4'-hydroxyphenyl)-amino-6,7-dimethoxyquinazoline | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| imatinib | Homo sapiens (human) | Kd | 0.0410 | 1 | 1 |
| triciribine phosphate | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| picropodophyllin | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| gefitinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| lestaurtinib | Homo sapiens (human) | Kd | 3.2570 | 1 | 1 |
| perifosine | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| vatalanib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| ruboxistaurin | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| canertinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| cyc 202 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| enzastaurin | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| erlotinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| lapatinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| sorafenib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| resveratrol | Homo sapiens (human) | Kd | 0.0540 | 1 | 1 |
| s 1033 | Homo sapiens (human) | Kd | 1.4840 | 1 | 1 |
| xl147 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| bms 387032 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| sf 2370 | Homo sapiens (human) | Kd | 4.0310 | 1 | 1 |
| tandutinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| dasatinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 2 |
| ha 1100 | Homo sapiens (human) | Kd | 30.0000 | 1 | 2 |
| 7-epi-hydroxystaurosporine | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| zd 6474 | Homo sapiens (human) | Kd | 30.0000 | 1 | 2 |
| imd 0354 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| 4,5,6,7-tetrabromobenzimidazole | Homo sapiens (human) | Kd | 0.0181 | 1 | 1 |
| sirolimus | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| alvocidib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| casein kinase ii | Homo sapiens (human) | Kd | 0.0364 | 1 | 1 |
| bosutinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| orantinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| su 11248 | Homo sapiens (human) | Kd | 4.0220 | 1 | 1 |
| palbociclib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| vx680 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| cyc 116 | Homo sapiens (human) | Kd | 0.6480 | 1 | 1 |
| everolimus | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| ekb 569 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| axitinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| temsirolimus | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| on 01910 | Homo sapiens (human) | Kd | 15.2240 | 1 | 1 |
| av 412 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| telatinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 2 |
| y-39983 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| cp 547632 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| lenvatinib | Homo sapiens (human) | Kd | 1.5230 | 1 | 1 |
| pd 0325901 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| midostaurin | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| px-866 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| ripasudil | Homo sapiens (human) | Kd | 3.6990 | 1 | 1 |
| osi 930 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| scio-469 | Homo sapiens (human) | Kd | 9.9180 | 1 | 1 |
| cp 724714 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| hmn-214 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| tivozanib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| hki 272 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| tofacitinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| cediranib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| masitinib | Homo sapiens (human) | Kd | 0.4690 | 1 | 1 |
| ly-2157299 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| pazopanib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| azd 6244 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| su 14813 | Homo sapiens (human) | Kd | 30.0000 | 1 | 2 |
| bibw 2992 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| binimetinib | Homo sapiens (human) | Kd | 14.7000 | 1 | 1 |
| sotrastaurin | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| aee 788 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| saracatinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 2 |
| vx 702 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| crenolanib | Homo sapiens (human) | Kd | 0.0400 | 1 | 1 |
| tg100-115 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| cc 401 | Homo sapiens (human) | Kd | 1.4130 | 1 | 1 |
| bms 599626 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| exel-7647 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| volasertib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| azd 7762 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| regorafenib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| 6-[[5-fluoro-2-(3,4,5-trimethoxyanilino)-4-pyrimidinyl]amino]-2,2-dimethyl-4H-pyrido[3,2-b][1,4]oxazin-3-one | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| brivanib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| mp470 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| rgb 286638 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| np 031112 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| at 7519 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| bms-690514 | Homo sapiens (human) | Kd | 30.0000 | 1 | 2 |
| bi 2536 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| inno-406 | Homo sapiens (human) | Kd | 6.8690 | 1 | 1 |
| kw 2449 | Homo sapiens (human) | Kd | 3.5970 | 1 | 1 |
| danusertib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| abt 869 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| azd 8931 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| arq 197 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| azd 1152 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| pf 00299804 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| ridaforolimus | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| ch 4987655 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| 6-(5-((cyclopropylamino)carbonyl)-3-fluoro-2-methylphenyl)-n-(2,2-dimethylprpyl)-3-pyridinecarboxamide | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| cc-930 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| tak 285 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| idelalisib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| crizotinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| osi 906 | Homo sapiens (human) | Kd | 30.0000 | 1 | 2 |
| chir-265 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| motesanib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| fostamatinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| trametinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| mln8054 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| pf-562,271 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| jnj-26483327 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| ly2603618 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| tg100801 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| dactolisib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| bgt226 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| gsk 461364 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| azd 1152-hqpa | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| enmd 2076 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| e 7050 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| 2-amino-8-ethyl-4-methyl-6-(1H-pyrazol-5-yl)-7-pyrido[2,3-d]pyrimidinone | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| tak-901 | Homo sapiens (human) | Kd | 88.9030 | 1 | 1 |
| gdc-0973 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| buparlisib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| azd 1480 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| azd8330 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| pha 848125 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| ro5126766 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| fedratinib | Homo sapiens (human) | Kd | 4.3140 | 1 | 1 |
| gsk690693 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| 14-methyl-20-oxa-5,7,14,26-tetraazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8(27),9,11,16,21,23-decaene | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| azd5438 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| pf 04217903 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| gdc 0941 | Homo sapiens (human) | Kd | 1.0280 | 1 | 1 |
| icotinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| ph 797804 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| kx-01 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| mk 5108 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| cx 4945 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| cudc 101 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| arry-614 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| tak 593 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| mln 8237 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| sgx 523 | Homo sapiens (human) | Kd | 0.1240 | 1 | 1 |
| bms 754807 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| bms 777607 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| sgi 1776 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| pci 32765 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| ponatinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| amg 900 | Homo sapiens (human) | Kd | 3.3530 | 1 | 1 |
| mk-1775 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| AMG-208 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| quizartinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| at13148 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| tak 733 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| mk 2206 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| sns 314 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| lucitanib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| pf-04691502 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| n-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide | Homo sapiens (human) | Kd | 30.0000 | 1 | 2 |
| dcc-2036 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| cabozantinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| defactinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| ly2584702 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| incb-018424 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| poziotinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| asp3026 | Homo sapiens (human) | Kd | 6.3630 | 1 | 1 |
| entrectinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| pexidartinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| TAK-580 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| gsk 2126458 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| emd1214063 | Homo sapiens (human) | Kd | 0.8750 | 1 | 1 |
| pf 3758309 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| gdc 0980 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| azd2014 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| (5-(2,4-bis((3s)-3-methylmorpholin-4-yl)pyrido(2,3-d)pyrimidin-7-yl)-2-methoxyphenyl)methanol | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| plx4032 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| gsk 1363089 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| arry-334543 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| kin-193 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| mk 2461 | Homo sapiens (human) | Kd | 52.6320 | 1 | 1 |
| bay 869766 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| as 703026 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| baricitinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| dabrafenib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| pki 587 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| n-(3-fluoro-4-((1-methyl-6-(1h-pyrazol-4-yl)-1h-indazol-5 yl)oxy)phenyl)-1-(4-fluorophenyl)-6-methyl-2-oxo-1,2-dihydropyridine-3-carboxamide | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| ribociclib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| mk-8033 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| pha 793887 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| sb 1518 | Homo sapiens (human) | Kd | 0.0040 | 1 | 1 |
| abemaciclib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| mk-8776 | Homo sapiens (human) | Kd | 2.3590 | 1 | 1 |
| afuresertib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| gsk 1070916 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| jnj38877605 | Homo sapiens (human) | Kd | 0.3230 | 1 | 1 |
| dinaciclib | Homo sapiens (human) | Kd | 30.0000 | 1 | 2 |
| gilteritinib | Homo sapiens (human) | Kd | 1.7010 | 1 | 1 |
| alectinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| glpg0634 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| encorafenib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| bms-911543 | Homo sapiens (human) | Kd | 5.8640 | 1 | 1 |
| gsk2141795 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| azd8186 | Homo sapiens (human) | Kd | 30.0000 | 1 | 2 |
| byl719 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| cep-32496 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| rociletinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| ceritinib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| azd1208 | Homo sapiens (human) | Kd | 30.0000 | 1 | 2 |
| vx-509 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| debio 1347 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| volitinib | Homo sapiens (human) | Kd | 0.2060 | 1 | 1 |
| osimertinib | Homo sapiens (human) | Kd | 3.6580 | 1 | 1 |
| at 9283 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| otssp167 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| chir 258 | Homo sapiens (human) | Kd | 3.0110 | 1 | 1 |
| osi 027 | Homo sapiens (human) | Kd | 1.3900 | 1 | 1 |
| nintedanib | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
| bay 80-6946 | Homo sapiens (human) | Kd | 30.0000 | 1 | 1 |
Oxindole-based intraocular pressure reducing agents.Bioorganic & medicinal chemistry letters, , 08-15, Volume: 27, Issue:16, 2017
Synthesis of novel МТ3 receptor ligands via an unusual Knoevenagel condensation.Bioorganic & medicinal chemistry letters, , Dec-15, Volume: 22, Issue:24, 2012
Design and synthesis of naphthalenic derivatives as new ligands at the melatonin binding site MT3.European journal of medicinal chemistry, , Volume: 46, Issue:5, 2011
Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities.Journal of medicinal chemistry, , Apr-09, Volume: 52, Issue:7, 2009
Kinetic, thermodynamic and X-ray structural insights into the interaction of melatonin and analogues with quinone reductase 2.The Biochemical journal, , Jul-01, Volume: 413, Issue:1, 2008
A novel quantitative structure-activity relationship method to predict the affinities of MT3 melatonin binding site.European journal of medicinal chemistry, , Volume: 43, Issue:12, 2008
Synthesis of a novel series of benzocycloalkene derivatives as melatonin receptor agonists.Journal of medicinal chemistry, , Sep-12, Volume: 45, Issue:19, 2002
Synthesis of nitroindole derivatives with high affinity and selectivity for melatoninergic binding sites MT(3).Journal of medicinal chemistry, , Apr-25, Volume: 45, Issue:9, 2002
Non-kinase targets of protein kinase inhibitors.Nature reviews. Drug discovery, , Volume: 16, Issue:6, 2017
Affinity-Based Selectivity Profiling of an In-Class Selective Competitive Inhibitor of Acyl Protein Thioesterase 2.ACS medicinal chemistry letters, , Feb-09, Volume: 8, Issue:2, 2017
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Dabigatran and dabigatran ethyl ester: potent inhibitors of ribosyldihydronicotinamide dehydrogenase (NQO2).Journal of medicinal chemistry, , Apr-26, Volume: 55, Issue:8, 2012
Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities.Journal of medicinal chemistry, , Apr-09, Volume: 52, Issue:7, 2009
Kinetic, thermodynamic and X-ray structural insights into the interaction of melatonin and analogues with quinone reductase 2.The Biochemical journal, , Jul-01, Volume: 413, Issue:1, 2008
Synthesis of nitroindole derivatives with high affinity and selectivity for melatoninergic binding sites MT(3).Journal of medicinal chemistry, , Apr-25, Volume: 45, Issue:9, 2002
Novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2): crystal structures, biochemical activity, and intracellular effects of imidazoacridin-6-ones.Journal of medicinal chemistry, , Oct-13, Volume: 54, Issue:19, 2011
Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2.Bioorganic & medicinal chemistry letters, , May-01, Volume: 20, Issue:9, 2010
Novel inhibitors of NRH:quinone oxidoreductase 2 (NQO2): crystal structures, biochemical activity, and intracellular effects of imidazoacridin-6-ones.Journal of medicinal chemistry, , Oct-13, Volume: 54, Issue:19, 2011
Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2.Bioorganic & medicinal chemistry letters, , May-01, Volume: 20, Issue:9, 2010
[no title available]Journal of medicinal chemistry, , 03-24, Volume: 65, Issue:6, 2022
Discovery of potent 4-aminoquinoline hydrazone inhibitors of NRH:quinoneoxidoreductase-2 (NQO2).European journal of medicinal chemistry, , Nov-15, Volume: 182, 2019
Evaluation of analogues of furan-amidines as inhibitors of NQO2.Bioorganic & medicinal chemistry letters, , 05-01, Volume: 28, Issue:8, 2018
Non-symmetrical furan-amidines as novel leads for the treatment of cancer and malaria.European journal of medicinal chemistry, , Mar-23, Volume: 111, 2016
Design, synthesis, biological and structural evaluation of functionalized resveratrol analogues as inhibitors of quinone reductase 2.Bioorganic & medicinal chemistry, , Oct-01, Volume: 21, Issue:19, 2013
Bioactive compounds from the fern Lepisorus contortus.Journal of natural products, , Feb-25, Volume: 74, Issue:2, 2011
Triazoloacridin-6-ones as novel inhibitors of the quinone oxidoreductases NQO1 and NQO2.Bioorganic & medicinal chemistry, , Jan-15, Volume: 18, Issue:2, 2010
Imidazoacridin-6-ones as novel inhibitors of the quinone oxidoreductase NQO2.Bioorganic & medicinal chemistry letters, , May-01, Volume: 20, Issue:9, 2010
Synthesis of casimiroin and optimization of its quinone reductase 2 and aromatase inhibitory activities.Journal of medicinal chemistry, , Apr-09, Volume: 52, Issue:7, 2009
Kinetic, thermodynamic and X-ray structural insights into the interaction of melatonin and analogues with quinone reductase 2.The Biochemical journal, , Jul-01, Volume: 413, Issue:1, 2008
Non-kinase targets of protein kinase inhibitors.Nature reviews. Drug discovery, , Volume: 16, Issue:6, 2017
Affinity-Based Selectivity Profiling of an In-Class Selective Competitive Inhibitor of Acyl Protein Thioesterase 2.ACS medicinal chemistry letters, , Feb-09, Volume: 8, Issue:2, 2017
The target landscape of clinical kinase drugs.Science (New York, N.Y.), , 12-01, Volume: 358, Issue:6367, 2017
Enables
This protein enables 12 target(s):
| Target | Category | Definition |
|---|
| dihydronicotinamide riboside quinone reductase activity | molecular function | Catalysis of the reaction: 1-(beta-D-ribofuranosyl)-1,4-dihydronicotinamide + a quinone = 1-(beta-D-ribofuranosyl)nicotinamide + a hydroquinone. [RHEA:12364] |
| protein binding | molecular function | Binding to a protein. [GOC:go_curators] |
| zinc ion binding | molecular function | Binding to a zinc ion (Zn). [GOC:ai] |
| electron transfer activity | molecular function | A molecular function representing the directed movement of electrons from one molecular entity to another, typically mediated by electron carriers or acceptors, resulting in the transfer of energy and/or the reduction-oxidation (redox) transformation of chemical species. This activity is fundamental to various biological processes, including cellular respiration and photosynthesis, as well as numerous enzymatic reactions involved in metabolic pathways. [Wikipedia:Electron_transfer] |
| oxidoreductase activity | molecular function | Catalysis of an oxidation-reduction (redox) reaction, a reversible chemical reaction in which the oxidation state of an atom or atoms within a molecule is altered. One substrate acts as a hydrogen or electron donor and becomes oxidized, while the other acts as hydrogen or electron acceptor and becomes reduced. [GOC:go_curators] |
| oxidoreductase activity, acting on other nitrogenous compounds as donors | molecular function | Catalysis of an oxidation-reduction (redox) reaction in which a nitrogenous group, excluding NH and NH2 groups, acts as a hydrogen or electron donor and reduces a hydrogen or electron acceptor. [GOC:ai] |
| chloride ion binding | molecular function | Binding to a chloride ion (Cl-). [GOC:mah] |
| protein homodimerization activity | molecular function | Binding to an identical protein to form a homodimer. [GOC:jl] |
| FAD binding | molecular function | Binding to the oxidized form, FAD, of flavin-adenine dinucleotide, the coenzyme or the prosthetic group of various flavoprotein oxidoreductase enzymes. [GOC:mah] |
| melatonin binding | molecular function | Binding to melatonin. [GO_REF:0000067, GOC:mr, GOC:TermGenie, PMID:10379923] |
| resveratrol binding | molecular function | Binding to resveratrol. [GO_REF:0000067, GOC:TermGenie, PMID:18254726] |
| NAD(P)H dehydrogenase (quinone) activity | molecular function | Catalysis of the reaction: NAD(P)H + H+ + a quinone = NAD(P)+ + a quinol. [EC:1.6.5.2] |
Located In
This protein is located in 3 target(s):
| Target | Category | Definition |
|---|
| nucleoplasm | cellular component | That part of the nuclear content other than the chromosomes or the nucleolus. [GOC:ma, ISBN:0124325653] |
| cytosol | cellular component | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. [GOC:hjd, GOC:jl] |
| extracellular exosome | cellular component | A vesicle that is released into the extracellular region by fusion of the limiting endosomal membrane of a multivesicular body with the plasma membrane. Extracellular exosomes, also simply called exosomes, have a diameter of about 40-100 nm. [GOC:BHF, GOC:mah, GOC:vesicles, PMID:15908444, PMID:17641064, PMID:19442504, PMID:19498381, PMID:22418571, PMID:24009894] |
Active In
This protein is active in 1 target(s):
| Target | Category | Definition |
|---|
| cytosol | cellular component | The part of the cytoplasm that does not contain organelles but which does contain other particulate matter, such as protein complexes. [GOC:hjd, GOC:jl] |
Involved In
This protein is involved in 1 target(s):
| Target | Category | Definition |
|---|
| quinone catabolic process | biological process | The chemical reactions and pathways resulting in the breakdown of quinone. [GOC:go_curators, GOC:pr, GOC:TermGenie] |